Brief: Dyadic Provides Phase 1 Clinical Trial Update For Its RBD Vaccine Candidate

Dyadic International

24/07/2023 14:42

July 24 (Reuters) - Dyadic International Inc  DYAI.O :
    * DYADIC PROVIDES PHASE 1 CLINICAL TRIAL UPDATE FOR
ITS RECOMBINANT PROTEIN RBD VACCINE CANDIDATE
    * DYADIC INTERNATIONAL INC- NO MAJOR VACCINE-RELATED SAFETY
CONCERNS FOR EITHER OF TWO DOSE LEVELS
    * DYADIC INTERNATIONAL INC- PHASE 1 FULL STUDY REPORT
EXPECTED IN
Q4, 2023
    * DYADIC INTERNATIONAL INC- DYAI-100 RBD COVID-19 BOOSTER
VACCINE
PRODUCED IMMUNE RESPONSE AT BOTH DOSE LEVELS

Source text for Eikon:  ID:nGNX9VPXlF 
Further company coverage:  DYAI.O 

 ((Reuters.Briefs@thomsonreuters.com;))